pneumonia epidemiology after PCV introduction. 48 Introduction 49 Rationale 50 Pneumonia is one of the leading causes of childhood deaths globally, particularly in Africa (1). 51 Despite consistent year-on-year reduction in the total number of childhood deaths attributed 52 to pneumonia or lower respiratory infections, pneumonia still account for a significant 53 proportion of all childhood deaths globally. According to the World Health Oganization (WHO) 54 estimates, the African region accounted for about half of the 808,694 childhood deaths due to 55 lower respiratory infections. Annually over a 100 million cases of pneumonia are reported in 56 children less than five years of age, mostly in poor countries in . 57 Streptococcus pneumonia is the major cause of childhood pneumonia deaths and is the leading 58 cause of vaccine-preventable child deaths globally(5-7). Pneumococcal pneumonia causes 59 between 1 and 4 million episodes of pneumonia in Africa yearly (8) . Streptococcus pneumonia is 60 a gram-positive diplococcic that usually colonizes the human upper respiratory tract and can 61 occasionally be found in the airways of other animals (9) (10) (11) (12) (13) (14) . Infection occurs mostly through 62 autoinfection when the bacteria is translocate to the normally sterile environment of the lower 63 tract and evades host immune defences (9, 12, 14, 15) . There are 97 serotypes of S. pneumoniae 64 currently known based on their polysaccharide capsule antigen (16) . The 97 serotypes differ in 65 carriage potential and propensity to cause invasive disease including pneumonia, otitis media 66 and meningitis (17, 18) , with the thirteen most common serotypes accounting for 70 -75% of 67 invasive pneumococcal disease globally (8, 18, 19) .
Pneumococcal conjugate vaccines (PCV) have been licensed since 2000; previous 69 polysaccharide-based vaccines were found to have poor immunogenicity in children (8) . An 70 initial 7-valent PCV included serotypes 4, 6B, 9V, 14, 18C, 19F and 23F providing cover against 71 67% of disease-causing serotypes. The 10-valent and 13-valent PCV include in addition to the 7-72 valent serotypes 1, 3 and 7F; and 1, 3, 7F, 19A, 6A and 3. The 10-valent and 13-valent vaccine 73 serotypes cover over 80% of invasive disease-causing serotypes (8, 20, 21) . Sub-Saharan African 74 countries like South-Africa and The Gambia introduced the 7-valent PCV into routine infant 75 vaccination schedule in the later part of the last decade (22, 23) . The WHO recommends the 10-76 or 13-valent PCV for routine infant immunization. Many countries in Africa through the support 77 of Global Alliance for Vaccination and Immunization (GAVI) have incorporated pneumococcal 78 vaccines into their expanded program of Immunization (EPI) schedules. With vaccine coverage 79 above 90% in most countries in sub-Saharan Africa, PCV vaccination is associated with a 80 significant decline in invasive pneumococcal disease incidence globally and at individual country 81 level (16, 22, 23) . The benefit of vaccines post introduction is usually estimated by measuring 82 vaccine effectiveness or vaccine impact. Vaccine effectiveness measures the reduction in 83 disease rates in the context of routine real world use; this is usually done in the context of case-84 control or Cohort studies. Vaccine impact on the other hand quantifies the reduction in disease 85 rate at the population level following vaccine introduction. Vaccine impact is usually measured 86 by quasi-randomised methods like pre-post studies and interrupted time series analysis(24) 87 The impact of vaccination on pneumococcal pneumonia has been clearly demonstrated; 88 however its impact on clinical and radiological pneumonia has been more modest(23). Studies 89 in sub-Saharan Africa have reported varied measures of vaccine effectiveness and impact. 90 Overall, there is overwhelming evidence of effectiveness against invasive pneumococcal disease 91 with significant decline in disease after introduction of the vaccine (25) (26) (27) (28) (29) included only studies where the outcome was assessed 3 years or more after vaccine 118 introduction.
119
Studies using 7-valent or 9-valent PCV, review papers, clinical trials and papers without 120 available versions in English were excluded. We excluded 7-valent PCV studies because these 121 vaccines were shown to have limted serotype coverage in sub-Saharan Africa.
122
Information sources: 123 We conducted a search of peer-reviewed and grey literature relating to the study question. 163 We assessed the quality of each study included in the review. For the case-control studies 164 assessing vaccine effectiveness, we used the National Heart, Lung and Blood Institute Quality 165 assessment tool for case-control studies. We adapted the National Heart, Lung and Blood outcome. This is likely due to the fact that radiological pneumonia is more specific for 282 pneumococcal disease. Overall, there was a consistent decline in pneumococcal pneumonia 283 cases in the post-vaccine period in reported impact studies (27, 36, 42) . Two studies that 284 reported on vaccine effect in HIV infected children showed that pneumococcal vaccine had 285 similar impact as with HIV uninfected children (36, 41) . 286 The overall trend in the findings from this review is similar to reports from other parts of the 287 world. Meta-analyses from other regions have found modest decline in clinical and radiological 288 pneumonia hospitalizations. A meta-analysis using global data from 12 pre-post and time series 289 studies produced a pooled reduction in hospitalization rates for clinical pneumonia of 17% and 290 9% in the under 24 months and 24 -59 months' age groups. However, they reported a more 291 significant decline in hospitalization rates due to radiological pneumonia of 31% and 24% in the 292 same age groups(48). Another meta-analysis of invasive pneumococcal disease hospitalization 293 in Latin America showed a pooled vaccine effectiveness of 8.8% -37.8% for radiological 294 pneumonia and 7.4% -20.6% for clinical pneumonia. A randomised placebo-controlled trial on 295 9-valent vaccine showed vaccine effectiveness of 37% based on per-protocol population(49).
Risk of bias in individual studies
Overall, it appears that pneumococcal vaccination has its greatest impact in preventing the 297 more severe forms of pneumonia for which children are likely to be hospitalised. This is 298 probably due to the finding that bacterial pathogens are more likely to cause severe 299 pneumonia(50). The minimal impact on clinical pneumonia might suggest a corresponding 300 increase in other forms of pneumonia or due to serotype replacement(51-53). We observed an 301 age-related trend in vaccine effect with the 12 -23 months age group experiencing the greatest 302 benefit. This might be due in part to a greater proportion of children under 12 months having 303 not completed their vaccination schedules; and potentially waning immunity in the older age 304 groups(54). 305 Limitations 306 This review has some limitations that have to be considered when interpreting our findings. 307 First was the inconsistency in the definition of pneumonia outcomes between studies, which 308 made combining the impact measured between studies impractical. While some studies used It is also important to note that while we set out to evaluate the impact of 10-valent and 13-318 valent vaccines, all of the study locations except in Kenya had a period of 7-valent vaccine use. 319 Therefore, is it impossible to separate the effect of the 7-valent from the 10-and 13-valent 320 vaccines since the 7-valent PCV might have changed the pre-existing disease trend. Publication bias is one potential limitation of this review; however, we do not believe that it 328 had a significant influence on the findings. This is because we searched multiple databases and 329 search engines to retrieve papers; we also included journals that published African studies and 330 grey-literature. It is therefore fair to assume that the effect of publication bias was minimal in this review. Due to limited resources we were unable to include studies published in other 332 languages; hence, language bias cannot be ruled out in our review. 333 Conclusion 334 To the best of our knowledge this is the first systematic attempt at synthesizing the impact and 335 effectiveness of routine pneumococcal vaccination on childhood pneumonia from this region. 336 The 10-and 13-valent PCV use as part of infant immunization is effective in preventing the 337 more severe forms of childhood pneumonia. 
